Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide

Science Translational Medicine

Volumn 5, Issue 211, 2013, Pages

  Kanakry, Christopher G ^a   Ganguly, Sudipto ^a   Zahurak, Marianna ^a   Bolaños Meade, Javier ^a   Thoburn, Christopher ^a   Perkins, Brandy ^a   Fuchs, Ephraim J ^a   Jones, Richard J ^a   Hess, Allan D ^a   Luznik, Leo ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE INHIBITOR; CD4 ANTIGEN; CD45RA ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIETHYLAMINOBENZALDEHYDE; IMMUNOSUPPRESSIVE AGENT; MAFOSFAMIDE; RAPAMYCIN; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ CD45RA- FOXP3+HI EFFECTOR REGULATORY T CELL; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; DRUG SENSITIZATION; EFFECTOR CELL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MALE; MEMORY CD4+ FOXP3+ T CELL; MEMORY T LYMPHOCYTE; MIXED LYMPHOCYTE REACTION; MOUSE; MYELOABLATIVE CONDITIONING; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; XENOGRAFT;

ADULT; ALDEHYDE DEHYDROGENASE; ANTINEOPLASTIC AGENTS, ALKYLATING; BONE MARROW TRANSPLANTATION; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; LYMPHOCYTE CULTURE TEST, MIXED; MALE; MIDDLE AGED; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 84890082174     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3006960     Document Type: Article

References (49)

1. M. K. Jenkins, R. H. Schwartz, D. M. Pardoll, Effects of cyclosporine A on T cell development and clonal deletion. Science 241, 1655-1658 (1988).
2. A. Bacigalupo, M. T. Van Lint, D. Occhini, F. Gualandi, T. Lamparelli, G. Sogno, E. Tedone, F. Frassoni, J. Tong, A. M. Marmont, Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 77, 1423-1428 (1991).
3. L. Luznik, R. J. Jones, E. J. Fuchs, High-dose cyclophosphamide for graft-versus-host disease prevention. Curr. Opin. Hematol. 17, 493-499 (2010).
4. L. Luznik, P. V. O'Donnell, H. J. Symons, A. R. Chen, M. S. Leffell, M. Zahurak, T. A. Gooley, S. Piantadosi, M. Kaup, R. F. Ambinder, C. A. Huff, W. Matsui, J. Bolaños-Meade, I. Borrello, J. D. Powell, E. Harrington, S. Warnock, M. Flowers, R. A. Brodsky, B. M. Sandmaier, R. F. Storb, R. J. Jones, E. J. Fuchs, HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol. Blood Marrow Transplant. 14, 641-650 (2008).
5. J. Leventhal, M. Abecassis, J. Miller, L. Gallon, K. Ravindra, D. J. Tollerud, B. King, M. J. Elliott, G. Herzig, R. Herzig, S. T. Ildstad, Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci. Transl. Med. 4, 124ra128 (2012).
6. L. Luznik, J. Bolaños-Meade, M. Zahurak, A. R. Chen, B. D. Smith, R. Brodsky, C. A. Huff, I. Borrello, W. Matsui, J. D. Powell, Y. Kasamon, S. N. Goodman, A. Hess, H. I. Levitsky, R. F. Ambinder, R. J. Jones, E. J. Fuchs, High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood 115, 3224-3230 (2010).
7. L. Luznik, E. J. Fuchs, High-dose, post-transplantation cyclophosphamide to promote grafthost tolerance after allogeneic hematopoietic stem cell transplantation. Immunol. Res. 47, 65-77 (2010).
8. L. Luznik, S. Jalla, L. W. Engstrom, R. Iannone, E. J. Fuchs, Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood 98, 3456-3464 (2001).
9. M. Eto, H. Mayumi, Y. Tomita, Y. Yoshikai, Y. Nishimura, T. Maeda, T. Ando, K. Nomoto, Specific destruction of host-reactive mature T cells of donor origin prevents graft-versus-host disease in cyclophosphamide-induced tolerant mice. J. Immunol. 146, 1402-1409 (1991).
10. M. Eto, H. Mayumi, Y. Tomita, Y. Yoshikai, Y. Nishimura, K. Nomoto, Sequential mechanisms of cyclophosphamide-induced skin allograft tolerance including the intrathymic clonal deletion followed by late breakdown of the clonal deletion. J. Immunol. 145, 1303-1310 (1990).
11. Y. Tomita,H.Mayumi,M. Eto, K. Nomoto, Importance of suppressor T cells in cyclophosphamideinduced tolerance to the non-H-2-encoded alloantigens. Is mixed chimerism really required in maintaining a skin allograft tolerance? J. Immunol. 144, 463-473 (1990).
12. D. T. Le, E. M. Jaffee, Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: A current perspective. Cancer Res. 72, 3439-3444 (2012).
13. P. Hoffmann, J. Ermann, M. Edinger, C. G. Fathman, S. Strober, Donor-type CD4+CD25+ regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J. Exp. Med. 196, 389-399 (2002).
14. P. A. Taylor, C. J. Lees, B. R. Blazar, The infusion of ex vivo activated and expanded CD4+CD25+ immune regulatory cells inhibits graft-versus-host disease lethality. Blood 99, 3493-3499 (2002).
15. J. M. Magenau, X. Qin, I. Tawara, C. E. Rogers, C. Kitko, M. Schlough, D. Bickley, T. M. Braun, P. S. Jang, K. P. Lowler, D. M. Jones, S. W. Choi, P. Reddy, S. Mineishi, J. E. Levine, J. L. Ferrara, S. Paczesny, Frequency of CD4+CD25hiFOXP3+ regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease. Biol. Blood Marrow Transplant. 16, 907-914 (2010).
16. Y. Miura, C. J. Thoburn, E. C. Bright, M. L. Phelps, T. Shin, E. C. Matsui, W. H. Matsui, S. Arai, E. J. Fuchs, G. B. Vogelsang, R. J. Jones, A. D. Hess, Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood 104, 2187-2193 (2004).
17. K. Rezvani, S. Mielke, M. Ahmadzadeh, Y. Kilical, B. N. Savani, J. Zeilah, K. Keyvanfar, A. Montero, N. Hensel, R. Kurlander, A. J. Barrett, High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 108, 1291-1297 (2006).
18. C. G. Brunstein, J. S. Miller, Q. Cao, D. H. McKenna, K. L. Hippen, J. Curtsinger, T. Defor, B. L. Levine, C. H. June, P. Rubinstein, P. B. McGlave, B. R. Blazar, J. E. Wagner, Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: Safety profile and detection kinetics. Blood 117, 1061-1070 (2011).
19. M. Di Ianni, F. Falzetti, A. Carotti, A. Terenzi, F. Castellino, E. Bonifacio, B. Del Papa, T. Zei, R. I. Ostini, D. Cecchini, T. Aloisi, K. Perruccio, L. Ruggeri, C. Balucani, A. Pierini, P. Sportoletti, C. Aristei, B. Falini, Y. Reisner, A. Velardi, F. Aversa, M. F. Martelli, Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 117, 3921-3928 (2011).
20. S. L. Zeger, K. Y. Liang, Longitudinal data analysis for discrete and continuous outcomes. Biometrics 42, 121-130 (1986).
21. J. Storek, M. A. Dawson, B. Storer, T. Stevens-Ayers, D. G. Maloney, K. A. Marr, R. P. Witherspoon, W. Bensinger, M. E. Flowers, P. Martin, R. Storb, F. R. Appelbaum, M. Boeckh, Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 97, 3380-3389 (2001).
22. M. Miyara, Y. Yoshioka, A. Kitoh, T. Shima, K. Wing, A. Niwa, C. Parizot, C. Taflin, T. Heike, D. Valeyre, A. Mathian, T. Nakahata, T. Yamaguchi, T. Nomura, M. Ono, Z. Amoura, G. Gorochov, S. Sakaguchi, Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 30, 899-911 (2009).
23. N. E. Sladek, J. F. Powers, G. M. Grage, Half-life of oxazaphosphorines in biological fluids. Drug Metab. Dispos. 12, 553-559 (1984).
24. A. Emadi, R. J. Jones, R. A. Brodsky, Cyclophosphamide and cancer: Golden anniversary. Nat. Rev. Clin. Oncol. 6, 638-647 (2009).
25. R. J. Jones, J. P. Barber, M. S. Vala, M. I. Collector, S. H. Kaufmann, S. M. Ludeman, O. M. Colvin, J. Hilton, Assessment of aldehyde dehydrogenase in viable cells. Blood 85, 2742-2746 (1995).
26. R. W. Storms, A. P. Trujillo, J. B. Springer, L. Shah, O. M. Colvin, S. M. Ludeman, C. Smith, Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity. Proc. Natl. Acad. Sci. U.S.A. 96, 9118-9123 (1999).
27. A. K. Marwaha, S. Q. Crome, C. Panagiotopoulos, K. B. Berg, H. Qin, Q. Ouyang, L. Xu, J. J. Priatel, M. K. Levings, R. Tan, Cutting edge: Increased IL-17-secreting T cells in children with newonset type 1 diabetes. J. Immunol. 185, 3814-3818 (2010).
28. M. R. Alison, N. J. Guppy, S. M. Lim, L. J. Nicholson, Finding cancer stem cells: Are aldehyde dehydrogenases fit for purpose? J. Pathol. 222, 335-344 (2010).
29. G. Muzio, M. Maggiora, E. Paiuzzi, M. Oraldi, R. A. Canuto, Aldehyde dehydrogenases and cell proliferation. Free Radic. Biol. Med. 52, 735-746 (2012).
30. P. Sagoo, N. Ali, G. Garg, F. O. Nestle, R. I. Lechler, G. Lombardi, Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells. Sci. Transl. Med. 3, 83ra42 (2011).
31. T. Alexander, A. Sattler, L. Templin, S. Kohler, C. Gross, A. Meisel, B. Sawitzki, G. R. Burmester, R. Arnold, A. Radbruch, A. Thiel, F. Hiepe, Foxp3+ Helios+ regulatory T cells are expanded in active systemic lupus erythematosus. Ann. Rheum. Dis. 72, 1549-1558 (2013).
32. K. N. Wu, R. V. Emmons, M. P. Lisanti, J. L. Farber, A. K.Witkiewicz, Foxp3-expressing T regulatory cells andmast cells in acute graft-versus-host disease of the skin. Cell Cycle 8, 3593-3597 (2009).
33. C. Fondi, C. Nozzoli, S. Benemei, G. Baroni, R. Saccardi, S. Guidi, P. Nicoletti, B. Bartolozzi, N. Pimpinelli, M. Santucci, A. Bosi, D. Massi, Increase in FOXP3+ regulatory T cells in GVHD skin biopsies is associated with lower disease severity and treatment response. Biol. Blood Marrow Transplant. 15, 938-947 (2009).
34. P. Ratajczak, A. Janin, R. Peffault de Latour, C. Leboeuf, A. Desveaux, K. Keyvanfar, M. Robin, E. Clave, C. Douay, A. Quinquenel, C. Pichereau, P. Bertheau, J. Y. Mary, G. Socié, Th17/Treg ratio in human graft-versus-host disease. Blood 116, 1165-1171 (2010).
35. F. Ghiringhelli, N. Larmonier, E. Schmitt, A. Parcellier, D. Cathelin, C. Garrido, B. Chauffert, E. Solary, B. Bonnotte, F. Martin, CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 34, 336-344 (2004).
36. R. J. North, Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J. Exp. Med. 155, 1063-1074 (1982).
37. S. Brode, T. Raine, P. Zaccone, A. Cooke, Cyclophosphamide-induced type-1 diabetes in the NODmouse is associated with a reduction of CD4+CD25+Foxp3+ regulatory T cells. J. Immunol. 177, 6603-6612 (2006).
38. M. E. Lutsiak, R. T. Semnani, R. De Pascalis, S. V. Kashmiri, J. Schlom, H. Sabzevari, Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by lowdose cyclophosphamide. Blood 105, 2862-2868 (2005).
39. J. P. Machiels, R. T. Reilly, L. A. Emens, A. M. Ercolini, R. Y. Lei, D. Weintraub, F. I. Okoye, E. M. Jaffee, Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage- colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res. 61, 3689-3697 (2001).
40. C. Winzler, M. Fantinato, M. Giordan, E. Calore, G. Basso, C. Messina, CD4+ T regulatory cells are more resistant to DNA damage compared to CD4+ T effector cells as revealed by flow cytometric analysis. Cytometry A 79, 903-911 (2011).
41. L. Strauss, M. Czystowska, M. Szajnik, M. Mandapathil, T. L. Whiteside, Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin. PLoS One 4, e5994 (2009).
42. D. Mougiakakos, C. C. Johansson, R. Kiessling, Naturally occurring regulatory T cells show reduced sensitivity toward oxidative stress-induced cell death. Blood 113, 3542-3545 (2009).
43. X. Mu, C. Isaac, T. Schott, J. Huard, K. Weiss, Rapamycin inhibits ALDH activity, resistance to oxidative stress, and metastatic potential in murine osteosarcoma cells. Sarcoma 2013, 480713 (2013).
44. J. A. Hall, J. R. Grainger, S. P. Spencer, Y. Belkaid, The role of retinoic acid in tolerance and immunity. Immunity 35, 13-22 (2011).
45. C. G. Brunstein, E. J. Fuchs, S. L. Carter, C. Karanes, L. J. Costa, J. Wu, S. M. Devine, J. R. Wingard, O. S. Aljitawi, C. S. Cutler, M. H. Jagasia, K. K. Ballen, M. Eapen, P. V. O'Donnell; Blood and Marrow Transplant Clinical Trials Network, Alternative donor transplantation after reduced intensity conditioning: Results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 118, 282-288 (2011).
46. M. Goldstein, W. P. Roos, B. Kaina, Apoptotic death induced by the cyclophosphamide analogue mafosfamide in human lymphoblastoid cells: Contribution of DNA replication, transcription inhibition and Chk/p53 signaling. Toxicol. Appl. Pharmacol. 229, 20-32 (2008).
47. K. Bocian, J. Borysowski, P. Wierzbicki, J. Wyzgal, D. Klosowska, A. Bialoszewska, L. Paczek, A. Górski, G. Korczak-Kowalska, Rapamycin, unlike cyclosporine A, enhances suppressive functions of in vitro-induced CD4+CD25+ Tregs. Nephrol. Dial. Transplant. 25, 710-717 (2010).
48. J. J. Coenen, H. J. Koenen, E. van Rijssen, L. B. Hilbrands, I. Joosten, Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells. Blood 107, 1018-1023 (2006).
49. S. B. Porter, B. Liu, J. Rogosheske, B. L. Levine, C. H. June, V. K. Kohl, J. E. Wagner, J. S. Miller, B. R. Blazar, Suppressor function of umbilical cord blood-derived CD4+CD25+ T-regulatory cells exposed to graft-versus-host disease drugs. Transplantation 82, 23-29 (2006).